On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review
نویسندگان
چکیده
UNLABELLED Off-label intravitreal use of the vascular endothelial growth factor (VEGF) antibody bevacizumab for retinopathy of prematurity (ROP) increases despite lack of studies on safety, pharmacokinetics and dosage in developing individuals. Systemic absorption has been considered negligible. A literature search was performed with emphasis on potential adverse systemic effects in developing individuals. CONCLUSION Intravitreal bevacizumab enters the general circulation, suppresses plasma VEGF levels and remains in the blood for more than 8 weeks in primates. Possible adverse effects on VEGF-dependent development must be considered.
منابع مشابه
[Off-label use of intravitreal bevacizumab for severe retinopathy of prematurity].
OBJECTIVE To examine the quality of evidence and the variability in the off-label use of intravitreal bevacizumab for retinopathy of prematurity (ROP). METHODS A wide review of the literature was performed using Pubmed, Medline, and Cochrane database, using the words vascular endothelial growth factor (VEGF), retinopathy of prematurity, treatment and bevacizumab. RESULTS Case reports, case ...
متن کاملA New Model to Describe the Single-dose Pharmacokinetics of Bevacizumab and Predict Its Multiple-Dose Pharmacokinetics in Beagle Dogs
Complex pharmacokinetic (PK) properties including nonlinear elimination were encountered by some monoclonal antibodies (mAbs), and classic compartment models sometimes failed to appropriately describe those properties. In this work, a new model was built on a comprehensive analysis of the complex elimination of mAbs. This new model was firstly utilized to fit with the single-dose plasma concent...
متن کاملA New Model to Describe the Single-dose Pharmacokinetics of Bevacizumab and Predict Its Multiple-Dose Pharmacokinetics in Beagle Dogs
Complex pharmacokinetic (PK) properties including nonlinear elimination were encountered by some monoclonal antibodies (mAbs), and classic compartment models sometimes failed to appropriately describe those properties. In this work, a new model was built on a comprehensive analysis of the complex elimination of mAbs. This new model was firstly utilized to fit with the single-dose plasma concent...
متن کاملAnti-Vascular Endothelial Growth Factor Preparations in the Treatment of Retinopathy of Prematurity: Balancing Risks and Benefits.
NEED AND PURPOSE OF REVIEW The standard of management of severe retinopathy of prematurity (ROP) is laser ablation of the peripheral retina. Intra-vitreal injection of anti- vascular endothelial growth factor antibodies has emerged as an alternative modality of treatment of ROP. The purpose of this review is to evaluate the current evidence on benefits and risks of using anti-VEGF antibodies fo...
متن کاملIntravitreal low-dosage bevacizumab for retinopathy of prematurity.
PURPOSE To report on the therapeutic effect of intravitreal low-dose bevacizumab for treatment for retinopathy of prematurity (ROP). METHODS The single-centre retrospective, non-comparative case series study included all infants who consecutively underwent intravitreal injection of 0.375 mg bevacizumab (0.03 ml) under light sedation in topical anaesthesia as therapy of ROP in zone I or zone I...
متن کامل